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In vivo functional imaging by means of positron emission tomography (PET) is the sole method for providing
a quantitative measurement of k-, i and d-opioid receptor-mediated signalling in the central nervous system.
During the last two decades, measurements of changes to the regional brain opioidergic neuronal activationç
mediated by endogenously produced opioid peptides, or exogenously administered opioid drugsçhave been
conducted in numerous chronic pain conditions, in epilepsy, as well as by stimulant- and opioidergic drugs.
Although several PET-tracers have been used clinically for depiction and quantification of the opioid receptors
changes, the underlying mechanisms for regulation of changes to the availability of opioid receptors are still
unclear. After a presentation of the general signalling mechanisms of the opioid receptor system relevant for
PET, a critical survey of the pharmacological properties of some currently available PET-tracers is presented.
Clinical studies performed with different PET ligands are also reviewed and the compound-dependent findings
are summarized. An outlook is given concluding with the tailoring of tracer properties, in order to facilitate for
a selective addressment of dynamic changes to the availability of a single subclass, in combination with an opti-
mization of the quantification framework are essentials for further progress in the field of in vivo opioid receptor
imaging.
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Abbreviations: ACC=anterior cingulate cortex; BP=binding potential; BPND =BP using reference tissue method;
Bavail=concentration of available receptor; CAF=carfentanil; DPN=diprenorphine; FC=frontal cortex;
FDPN=6-O-desmethyl-2-fluoroethyl-diprenorphine; FCyF=fluoro-cyclofoxy; fMRI=functional magnetic resonance
imaging; GPCR=guanine nucleotide-binding protein coupled receptor; KD=radioligand equilibrium dissociation constant;
MeNTl=methyl-naltrindole; NA=nucleus accumbens; NMDA=N-methyl-D-asparate; DV=volume of distribution;
DVR=volume of distribution ratio; VOI=volume of interest; SM1=primary sensorimotor cortex; SA=spectral analysis;
SPM=statistical parametric mapping; VT=vol umeofd ist ri but ion.
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Introduction
The non-invasive detection of photon pairs within a given
body volume affords an opportunity to study the function
of opioid receptors (ORs) within the central nervous system
(CNS) in vivo with positron emission tomography (PET).
Interest also exists in using PET for studying opioid bio-
chemistry and opioidergic neurotransmission in epilepsy,
pain processing and neurodegenerative disorders, including
its use for evaluation of more selective, improved analgesics,
anticonvulsants and neuroprotective agents. In addition,
PET may in principle be useful for a qualitative and
quantitative assessment of adaptions to the central opoid
receptors resulting from opioid and stimulant drug seeking
behaviour, development of compulsive drug use, tolerance
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tive relationship between brain biochemistry, receptor
occupancy and behavioural as well as therapeutic effects
would be helpful in the optimization of therapeutic proto-
cols, including the evaluation and development of new
pharmacological treatments. With an appropriate reporter
probe (Fig. 1) labelled with positron emitting radionuclides,
such as
11C( t½=20.3min), or
18F( t½=109.7min), an
in vivo depiction and quantification of CNS-contained
receptors may be derived from PET measurements of brain
radioactivity.
The design and development of radiolabelled compounds
that can be administered intravenously, enter the brain via
the blood stream and subsequently bind to specific targets
in the CNS constitute the current major challenge in the
field of radiopharmaceutical chemistry. Compounds suita-
ble for the in vivo assessment of opioid receptors (ORs)
in the CNS can potentially permit investigation of how
the functional receptor status in vivo correlates with neuro-
biological and neuropsychiatric parameters. In addition
to providing a review of the published clinical PET-studies
on ORs, we review in this article the properties of the
tracers available and the kinetic modelling framework
used for generating a quantitative measurement of ORs in
the brain.
General function of opioid receptors
Opioid-binding sites in the central nervous system were
proposed by Beckett and Casy (1954) and Portoghese
(1965), and demonstrated in mammalian brain tissue in
1973 by using radioligand-binding assays on isolated brain
tissue (Pert and Snyder, 1973; Simon et al., 1973). The
extensive pharmacological studies performed during the last
decades have uncovered a variety of opioid receptor (OR)
subtypes. To date, four ORs have been cloned, the mu-(m)
(MOP-R), kappa-(k) (KOP-R), delta-(d) (DOP-R) and the
NOP-R, the latter initially referred to as ORL-1 (Mollereau
et al., 1994), or nociceptin/orphanin FQ receptor (Meunier
et al., 1995). For a definition of the OR terminology see:
Dhawan et al. (1996) and http://www.iuphar.org.
The ORs are now known to be distributed widely in the
central nervous system (CNS) and in peripheral sensory
and autonomic nerves. Activation of ORs by endogenous
and exogenous ligands results in a multitude of physiolo-
gical functions and behaviours. Research has been con-
ducted on a wide array of molecular–biochemical effects
and neurochemical localization studies of endogenous
opioids and their receptors, i.e. attempts have been to
clarify the role of OR-mediated signalling mechanisms in
pain and analgesia, stress and social status, tolerance and
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Fig. 1 Radiolabelled compounds established for clinical PET-investigations of the opioid receptors.
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alcohol and drugs of abuse, CNS development and
endocrinology, mental illness and mood, seizures and
neurological disorders, electrical activity and neurophysiol-
ogy, general activity and locomotion, gastrointestinal, renal
and hepatic functions, cardiovascular responses, respiration
and thermoregulation and immunological responses [for
reviews, see: van Ree et al. (1999); Law et al. (2000);
Williams et al. (2001)].
Opioid receptors and their ligands
There are three groups of endogenous opioid peptide
ligands; methionine- and leucine-enkephalin (derived from
proenkephalin), dynorphins-A and B and neo-endorphin
(derived from pro-dynorphin) and b-endorphin (derived
from pro-opiomelanocortin). Methionine-enkephalin (met-
enk) and leucine-enkephalin (leu-enk) have pronounced
affinity for d- and m-OR [inhibition constants, Ki,s, in the
range of 0.6–4nM (Raynor et al., 1994)] and very low
affinity (>1mM) for k-OR. The dynorphins preferentially
recognizes k-ORs [dynorphine A; Ki,k=0.5nM; Ki,m=32;
Ki,d>1000nM (Raynor et al., 1994)] while b-endorphin
displays m and d recognition [Km=Ki,d 1nM; Ki,k=52nM
(Raynor et al., 1994)]. Two endogenous peptides, endo-
morphin-1 and -2, have high and selective affinity for m-OR
(Hackler et al., 1997; Zadina et al., 1997; Ki,m=0.34 and
0.69nM, respectively), are not derived from the above
precursors, but via a so far not completely clarified bio-
chemical pathway. For a recent review on endomorphines-1
and -2, see: Fichna et al. (2007). In general, agonists
selective for m-ORs or d-ORs are analgesic and rewarding,
whereas at least some k-OR-selective agonists produce
aversive effects like dysphoria and hallucinations.
Receptor subtypes of m-, d and k-ORs have been
proposed from the results of pharmacological in vitro and
in vivo studies (Knapp et al., 1995; Connor and Christie,
1999), but at present there is no molecular evidence to
account for a further subclassification. Only one example of
each of the m-, d and k-ORs has been cloned from a given
species (Knapp et al., 1995) although functional splice
variants of m-ORs have been discovered (Abbadie et al.,
2004; Pasternak et al., 2004; Pan et al., 2005). A recent
explanation for subclasses of m- d and k -OR subtypes has
evolved with the identification of OR hetero-dimers or
hetero-oligomers that appear to have properties different
from the monomeric receptors. Heterodimerization of ORs
has been shown to affect receptor trafficking and there are
also reports of heterodimerization of the ORs with other
classes of guanine nucleotide-binding protein-coupled
receptors (GPCRs) (Jordan et al., 2000; Devi, 2001;
Rios et al., 2001).
Opioidergic signalling mechanisms
As members of the heterotrimeric GPCRs, ORs are signal
transducers anchored to the cell surface plasma membrane;
in this manner, they connect receptors to effectors and
thus to intracellular signalling pathways [for a general
review of G protein signalling pathways see: Neves et al.
(2002) and for the opioid receptor system specifically
Connor and Christie (1999); Law et al. (2000)]. The GCPRs
have seven transmembrane domains, substantial intracel-
lular domains between the fifth and sixth transmembrane
segment, an extracellular N-terminal and an intracellular
C-terminal domain (Strader et al., 1994). There is evidence
for more than 20 types of G protein and different receptor
types apparently interacting preferentially with different
types of G protein (Gudermann et al., 1996).
G proteins consist of three distinct subunits, Ga,G b and
Gg (Neves et al., 2002). m-, d- and k-ORs interact
preferentially with the pertussis toxin-(PTX) sensitive
G proteins a-subunits of the Gi and Go family (Gi1-3 and
Go1-2) as well as two PTX-insensitive subunits [Gz and G16
(Simon et al., 1991; Connor and Christie, 1999 and
references cited therein]. As reviewed by others (Connor
and Christie, 1999) a differential coupling of the ORs to
most types G protein subtypes is in general marginal,
but preferential coupling of m-OR to Gi3 and of d-OR to
G16 relative to that of m-and k-OR have been observed.
When an agonist binds to an OR, the G protein is split
into two subunits, Ga and the Gbg (Fig. 2). Both subunits
activate intracellular second-messenger systems regulating
cellular components such as metabolic enzymes, ion
channels and the transcriptional machinery. The Gbg
subunit activates neuronal inwardly rectifying K
+-channels
and inhibits high threshold voltage-activated Ca
2+ channels,
leading to reduced excitability and inhibition of neuro-
transmitter release (Clapham and Neer, 1997). The Gi/o
a-subunit mediates an inhibition of intracellular adenylyl
cyclase and reduction of cyclic adenosine monophosphate
(cAMP) that also reduces neuronal membrane excitability
and regulates gene expression and the activity of cellular
phosphatates and kinases. Opioids can thus inhibit the
release of neurotransmitters, such as glutamate and sub-
stance P, at spinal and supraspinal level.
Through the activation of PTX-sensitive Gi/Go, opioids
have predominantly inhibitory effects on cells in the CNS.
Functionally, the endogenous opioids act as co-transmitters
modulating the effect of fast-acting neurotransmitters
(Siggins et al., 1986; Wagner et al., 1993; Simmons and
Chavkin 1996). It has been observed that opioids act
indirectly to excite neurons through a presynaptic inhibition
of GABA release, so-called disinhibition. In addition,
opioids cause direct excitatory actions such as increased
firing of action potentials, and/or increases in intracellular
calcium concentration.
Desensitization, downregulation and cellular
counteradaptations
It is currently believed that the intracellular response after
activation of a G protein-coupled OR involves a conserved
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additional specialized protein interactions. In this manner,
a regulation of response specificity and plasticity beyond
the mere ligand–receptor interaction is conferred. It is clear
that ORs, as is the case with many G protein-linked
receptors, are not static but cycle to and from the plasma
membrane (Figs 2 and 3). Receptors found in vesicular
membranes can be both newly synthesized or recycled
(Shuster et al., 1999). Receptor trafficking initiated by
agonist binding and internalization through the endosomal
pathway is currently held to be involved in desensitization
and/or recycling in a feedback inhibition that is dependent
on prior activity in any given terminal. The internalization
of the OR is agonist dependent: It appears that all of the
endogenous OR agonists and a most alkaloid agonists
(except morphine) are potent activators of OR internaliza-
tion regardless of their ability to induce G protein
activation [for review see Williams et al., (2001)].
In states of pain, the endogenous OR system is activated
as a part of our endogenous analgesic system and is the
target of administered opioid analgesic drugs. Morphine
and other m-OR agonists are still the analgesics of choice
for patients with cancer pain and the majority of patients
with chronic non-malignant pain (Eriksen et al., 2003;
Carr et al. 2004). However, a major drawback to a
continued use of these drugs is the potential development
of tolerance and dependence, the latter in both the psycho-
logical and physical context. An increase in the occurrence
of direct excitatory effects during chronic opioid treatment
or chronic increased opioid neuronal tonus can contribute
to the appearance of paradoxical opioid-mediated pain,
hyperalgesia and allodynia (Varga et al., 2003). Thus, adap-
tion to chronic OR stimulation may involve tolerance to
Gi/o-mediated inhibition (analgesia) coupled with sensitiza-
tion to excitatory (pronociceptive) opioid actions (Celerier
et al., 2001). It is likely that similar counteradaptations take
Fig. 2 An opioid agonist binds to an opioid G-protein-coupled opioid receptor (A) activating the G protein complex by a GDP to
G T Ps w i t c hi nt h eG a subunit (B). Activated Ga and Gb/Gg subunits move to regulate effectors (C^E) followed by phosphorylation of
the C-terminal end of the receptor by G-protein receptor kinase. Arrestin binds to the phosphorylated C-terminal and binds to
clathrin (F)f o l l o w e db y( G) phosphorylation of dynamin (D) by c-src resulting in closing of the endocytotic vesicle (H) which is formed
by invagination of a clathrin-coated pit.The receptor is dephosphorylated (I) and subsequently reinserted into the membrane (J).
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opioid analgesia, which may be very different in a state of
disease compared to a healthy brain and should therefore
be considered in the interpretation of the findings on OR
availability.
Cellular adaptation induced by a compound with
agonistic effect at ORs may involve several processes:
(1) Acute desensitization of OR due to effector coupling
and receptor internalization that develops during and
abates shortly after exposure to agonists (Fig. 2) Unlike
the membrane-contained ion channels, the pathway
mediating the intracellular signalling part of ORs
involves multiple protein–protein interactions, translo-
cations and phosphorylation events. It appears to be at
least three general pathways following the activation of
Gi/Go-linked receptors that eventually converge on the
activation Thus, activation kinetic of ORs is longer
than that for other effectors, but occurs over a period
of several minutes to 1–2h (Williams et al., 2001). The
significance of OR activation kinetic in PET studies
with [
11C]carfentanil and [
11C]diprenorphine has been
addressed recently (Greenwald et al., 2007; Hammers
et al., 2007; Scott et al., 2007a).
(2) The signalling pathways that lead to long-term
adaptation through an altered genetic expression may
be regarded as an effector system. Long-term desensi-
tization of receptor to effector coupling and down-
regulation of receptors that slowly develops and then
persists for many hours to days after removal of
agonists. Similarly, long-term treatment with opioid
antagonists has shown to upregulate opioid receptors
(Lesscher et al., 2003). Desensitization of the receptor
(the progressive loss of receptor function), can be
a consequence of multiple processes of receptor
uncoupling, internalization, degradation and recycling.
(3) Adaptations of intracellular signalling mechanisms
in opioid-sensitive neurons (Fig. 2). Phosphorylation
of agonist-activated receptors, subsequent arrestin
recruitment and uncoupling of the receptors from
G proteins are important processes in the modulation
of GPCR responsiveness (Ahn et al., 2003; Gainetdinov
et al., 2004). GPCRs can be targeted to clathrin-coated
pits for endocytosis. Internalized receptors can also
Fig. 3 Hypothetical sequence of events leading to changes in the receptor status and thus changes to the baseline (A)r e c e p t o rb i n d i n g
of a tracer due to increased occupancy (B) of endogenous or exogenous opioid ligands leading potentially also to the induction of lower
affinity states of the receptor (C) (decoupling/inactivation) and downregulation and reduced receptor expression (D).
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to lysosomes for degradation (Tsao and von, 2001;
Tsao et al., 2001).
(4) Counter-adaptations in neuronal circuitry (Williams
et al., 2001) such as m-agonist-dependent activation
of the N-methyl-D-asparate (NMDA)-receptor system
and stimulation of the k-OR system.
Pharmacokinetic and pharmacodynamic
considerations of PET-ligands
Modelling of radioligand kinetics
In order to be practically useful for quantification of the
target-receptor concentration, the time-dependent count
rate information collected by the PET-camera must be
converted into figures relating to binding parameters. Since
the signal detected represents total radioactivity, it includes
specific and non-specific binding as well as free ligand in
the tissue and a blood volume component. In order to
designate the contributions from each of these parameters,
reference has to be made either to the arterial concentration
of the ligand (corrected for radioactive metabolites) or to
a reference region within the brain with no or negligible
specific binding of the tracer in question, hence providing
a kinetic estimate of non-specific binding plus free ligand
concentration (as well as a blood volume component)
which is used as an input. The assumption of no specific
binding in a reference region is not valid for all tracers, and
especially not for non-selective OR ligands. Only for d-OR
selective tracers there is a valid reference region; the
cerebellum (Schadrack et al., 1999). The most frequently
used reference region for m-selective and non-selective
ligands, the occipital cortex, has low expression of m-OR,
intermediate of d- and k-ORs (Hiller and Fan, 1996). The
presence of specific binding in a reference region may
underestimate the calculated specific binding.
Traditional models have formal compartmental struc-
tures and the rate constants are estimated by using standard
non-linear least squares fitting techniques [for reviews see:
Ichise et al. (2001); Gunn et al. (2002); Laruelle et al.
(2002); Innis et al. (2007))]. Compartments describe the
tracer distribution in separate tissue entities (plasma, free,
non-specific bound, specific bound) and rate constants are
describing the exchange kinetic between these compart-
ments (Innis et al., 2007). Using a single scan, derived
parameters such as the volume of distribution (VT) (the ratio
of ligand concentration between tissue and plasma) or
binding potential (BP) (the equilibrium concentration
of specific binding as a ratio to some other reference
concentration) can be obtained and both are proportional
to the Bavail (concentration of available receptors) and KD
(equilibrium dissociation constant of the radioligand).
These models have generally been applied to a region of
interest, but analysis is prone to errors due to variations
in the selection of the image segments to be analysed,
which effectively further reduces considerably the spatial
resolution of the imaging techniques. These problems can
be circumvented by the generation of parametric voxel-
by-voxel binding images. This technique, however, is
difficult to apply for traditional models as well as being
computationally time consuming, prone to errors due to
local minima, and, at worst, unidentifiable if a large
number of parameters need to be derived.
It is in principle possible to independently estimate Bavail
and ligand KD, but these estimates require two imaging
studies, at low and high-receptor occupancy, in order to
identify specific and non-specific binding (Frost et al., 1989;
Smith et al., 1999). Low and high-receptor occupancy
can be achieved using a competitive drug (e.g. naloxone)
or ligand at high and low-specific activities. However,
ligands with agonistic properties at lower specific activity
(higher doses) might have unwanted pharmacological
effects and therefore not be applicable for PET studies.
Approximations have therefore been done using the activity
ratio between regions rich in receptors and relative to that
obtained in a region devoid (or of very low concentration)
of receptors (Frost, 1988) and is referred to as BPND.
Assuming the non-specific binding to be uniform, the ratio
at binding equilibrium is linearly proportional to the ratio
of Bavail/KD (Mintun et al., 1984).
There is a range of parametric imaging analysis
techniques, typically based on a compartmental description
of the tracer (Gunn et al., 2002). These range from expli-
citly specified compartmental structures (model driven) to
more flexible models derived from a general compartmental
description (data driven). Examples of model-driven
approaches include a one-tissue compartmental model for
the estimation of blood flow (Kety and Schmidt, 1948)
and two-tissue compartment models for 2-[
18F]fluoro-
deoxy-glucose ([
18F]FDG) (Sokoloff et al., 1977; Phelps
et al. 1979) trapping and receptor ligand binding (Mintun
et al., 1984). More complex compartment models have an
increasing number of unknown parameters to be estimated
and result in higher variability. For data-driven methods,
there exist graphical analyses (Gjedde, 1982; Patlak et al.,
1983; Patlak and Blasberg 1985; Logan et al., 1990, 1996),
spectral analysis (Cunningham and Jones, 1993) and
bootstrapped DEPICT (Gunn et al., 2002), among others.
Ligands with slow binding kinetics may produce ‘noisy’
standard compartment models because of flow dependency
(changes in transport rate will affect a compound that never
reaches equilibration) and the uncertainty of calculating the
later points in the kinetic curve. Data-driven methods such
as spectral analysis may for such ligands with slow kinetics
be more suitable (Cunningham and Jones, 1993).
Images and imagination: interpretation
of the specific binding
As described earlier, the mechanisms regulating receptor
expression and binding status are complex, and a PET-study
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for a change in the specific binding of the tracer. A derivation
of cellular and subcellular processes directly from a PET-
image is speculative and data from complementary methods
are required for validation of the PET data.
The interpretation of the receptor affinity-dependent
binding is complex and depends, as described earlier, on
the G protein-dependent affinity state of the GPCRs (Fig.
3C). This affinity state may further be influenced by
endogenous release of opioid peptides and/or administra-
tion of opioid receptor modulating drugs. As the agonist/
antagonist properties of a PET-tracer may dominate its
ability to discriminate between different states of the G
protein coupling of the OR. Agonist binding depends on
the conformational state of the receptor and agonists bind
preferably to the receptors in the high-affinity state, while
antagonists will bind to both high and low-affinity states.
This dependency implies that interpretation of changes to
the receptor presentation in vivo studies would benefit from
a consideration of the tracer’s agonistic properties in
addition to its subtype selectivity. In temporal lobe epilepsy,
an asymmetry in receptor binding between the left and
right side of the brain was identified using [
11C]carfentanil
([
11C]CAF) (m-selective agonist), but no asymmetry was
seen using [
11C]DPN (non-selective antagonist) (Frost
et al., 1988; Mayberg et al., 1991) or [
18F]fluoro-cyclofoxy
[
18F]FCyF (m- and k-OR antagonist) (Theodore et al.,
1992). These authors discussed the result as an issue of
selectivity; however, the agonistic and antagonistic proper-
ties of the ligands used may just as much contribute to the
differences.
In addition, a reduced receptor binding may be due to
receptor down-regulation, internalized (non-available if not
immediately recycled) (Fig. 3D) receptors or a pathological
change due for example, to neuronal damage or neurode-
generation. For the latter, distant changes may also develop
along the neuronal projections or even as an antero- or
retrograde transneuronal degeneration (Fig. 3E,F) (Chung
et al., 1990). A transneuronal degeneration may at least in
part explain changes in binding distant from a neuronal
lesion such as stroke (Willoch et al., 2004). In contrast, an
increase in receptor binding may be due to an upregulation
or activation of a possible receptor reserve (Fan et al.,
2003). The above-described mechanisms represent slow
changes due to neurodegeneration or chronic activation of
the neurotransmitter system.
Acute changes, due to release of neurotransmitter
in response to a specific stimulus, can be measured in
receptor-activation studies (Fig. 3B). Receptor-activation
studies can be performed comparing binding from two
separate scans, i.e. one at baseline and one activation/
intervention study; this has been the most frequently
reported approach. An alternative is the methodologically
more challenging scan protocol consisting of a bolus-
infusion administration of tracer, performed to achieve
equilibrium, where control-binding levels are determined.
Subsequently, a physical or mental stimulation is con-
ducted, or pharmacological challenge is administered, while
the infusion of radiotracer continues, and the change in
specific binding of the tracer is monitored. This approach
has been used to measure the difference in amphetamine-
induced dopamine release between healthy controls and
patients with schizophrenia (Watabe et al., 2000) and
recently for measuring release of endogenous opioid
peptides during a state of sadness (Zubieta et al., 2003a, b).
Again, the change in receptor binding between the two
measured states may be dependent on both the number of
available receptor-binding sites as well as the affinity state
of the receptor. The available binding receptor sites (Bavail)
is reduced by both increased occupancy of released
endogenous opioid peptides and internalized receptors.
The m-OR agonist [
11C]CAF is likely to bind preferentially
to receptors in high-affinity states, coupled to G proteins.
A lower concentration of high-affinity receptors would be
expected after an opioid peptide release.
A pharmacological interaction between a PET ligand and
an exogenously administered ligand with an affinity for the
target ORs will follow the same biological rules, making the
observed changes dependent upon the selectivity and
agonistic property of both the ligand and the administered
substance. The dependency of the choice of biological
model as well as the properties of the radiotracer on the
outcome should therefore be carefully considered.
Despite a great development in mathematical modelling
and advanced data processing of tracer kinetics, there is no
standardized way to publish data from clinical studies.
From Table 1 it can be seen that 18 of the 51 published
studies have applied the logistically simplest approach,
i.e. the ratio method, and 17 of the studies have used a
non-invasive Logan plot. Both of these models do not need
a generation of an arterial input function. Sixteen of the
studies made use of arterial blood sampling to acquire an
arterial input function applied for compartmental model-
ling or spectral analysis. In recent years it has become
routine to produce parametric maps of the whole brain
data, and not only from drawn volumes of interest (VOIs)
(Table 1). The validity of using the whole brain versus
VOI was demonstrated by Weeks et al. (1997) in a study
of Huntington’s disease using [
11C]DPN binding. Whole
brain parametric maps make it possible to perform further
standardized post-processing (e.g. NEUROSTAT and SPM),
which may make the statistical analyses more standardized
and less dependent on the observer. A practical problem
is that the originally calculated parameters of perfusion and
receptor binding may be manipulated in the image analyses.
Several authors normalize the pixel values, whereas others
are more conservative and keep the original parametric
values. In principle, parametric data are already normalized
to a non-specific region or to blood. A normalization prior
to statistical processing (typically to whole brain values,
proportional scaling) may reduce variance, but at the same
time remove the quantification element inherent to kinetic
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Study Aim Ligand Modelling/statistical
analysis/group size
Main findings Interpretation/comments
Neurochemical mapping
Jones et al.,1991 Study of OR-binding in
relation to the lateral
and medial pain system.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Ratio method, BPND/VOI/
n=2
High OR binding in medial pain system
and low OR binding in lateral pain
system (SM1).
The medial pain system is likely to be
more susceptible to exogenous and
endogenous opioid neuromodulation
than the so-called lateral pain system.
Baumgartner
et al.,2 0 0 6
Study of OR-binding in
relation to the lateral
and medial pain system,
focus on secondary
sensory cortex.
[
18F]FDPN(m-, k-
and d-a n t a g o n i s t )
Non-invasive Logan plot,
BPND/VOI/n=1 1
All structures of the operculo-insular
region (anterior and posterior insula,
and parietal and frontal operculum) have
high OR binding. Factor analysis revealed
high loadings on operculo-insular region,
ACC and putamen.
The operculo-insular region as part of
the lateral pain system is influenced by
opioids and displays a functional unit
together with ACC and putamen.
Vogt et al.,1995 Detailed analysis of
OR binding in cingulate
and adjacent cortex.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Invasive compartment
model,VT/VOI/n=3
Highest OR binding in ACC, rostral
cingulofrontal transition and frontal
cortices.There was a gradient from low
to high binding to caudal ACC, PCC and
superior frontal cortices.
Variations in binding may reflect func-
tional specializations such as low
binding in visuospatial areas and high
binding in areas processing affective
content.
Schadrack et al.,
1999
In vivo and in vitro stu-
dies of cerebellum OR
binding and mRNA.
Comparison of rat and
human.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Invasive SA, IRF60/VOI/
n=1 0
No OR in rat cerebellum, and low to
medium OR binding in human cerebellum.
In human brain, there is a differential
OR level in cerebellar cortex, vermis and
dentate nuclei, and absence of d-OR.
mRNA mainly observed in granule cells
and OR predominantly in the molecular
layer.
Presence of opioidergic mechanisms in
the human cerebellum in contrast
to the rat.
Smith et al.,1998 Regulation of m-OR
during the menstrual
cycle.
[
11C]CAF
(m-agonist)
Ratio method, BPND/VOI/
n=1 0inl ut ealandin
follicular phases.
No significant differences in m-OR binding
between phases of the menstrual cycle.
A negative correlationbetween circulating
levels of estradiol during the follicular
phase and m-OR measures in amygdala
and hypothalamus, regions regulating
GnRH pulsatility. LH pulse amplitude was
positively correlated with m-OR in the
amygdala, whereas LH pulse number was
negatively correlated with m-OR in this
same region.
These results suggest that amygdalar
m-ORs exert a modulatory effect on
GnRH pulsatility, and that circulating
levels of estradiol also regulate central
m-OR function.
Zubieta et al.,
1999
Examine age- and
gender-associated
variations in m-OR
binding.
[
11C]CAF
(m-agonist)
Ratio method, BPND/VOI/
n=40females,n=36
males
m-OR binding increase with age in
neocortical areas and the putamen.
Higher m-OR binding in women was
observed in a number of cortical and
subcortical areas, but declined in post-
menopausal women to levels below those
of men.
These data imply that both age and
gender are important variables of
the OR system.
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2000a
Gender differences
in OR binding
(healthy controls
and AD patients).
[
18F]FcyF (m and
k-antagonist)
Ratio method, BPND/VOI/
n=9females,n=1 5males
Less combined m-/k-OR binding in
thalamus in females compared to males.
Consistent with evidence that sexual
dimorphism exists with respect to
opiate pathways.
Epilepsy: focal
Frost et al.,1 988 St udyroleofm-OR in
temporallobe epilepsy.
[
11C]CAF
(m-agonist) and
[
18F]FDG(glucose
metabolism)
Ratio method, BPND/VOI/
n=8
Inter-ictal increased m-OR binding in
temporal neocortex and hypometabolism
ipsilateral to epileptogenic focus.
Hippocampus and amygdala had no
change in binding or metabolism.
Opioids may represent an anticonvul-
sant system that limits spread of
electrical activity.
Mayberg et al.,
1991
Study role of m-OR
(carfentanil) versus
non-selective OR
(diprenorphine) bind-
ing in temporal lobe
epilepsy.
[
11C]CAF(m-agonist)
and [
11C]DPN (m-,
k-a n dd-a n t a g o -
nist) and [
18F]FDG
(glucose
metabolism)
Ratio method, BPND/VOI/
n=1 1
Inter-ictal m-ORwas increased in tem-
poral neocortex and reduced in amygdala
ipsilateral to epileptogenic focus.
Non-selective OR binding exhibited no
alteration.FDG showed temporal lobe
hypometabolism.
The variation in pattern of carfentanil
and diprenorphine binding supports a
differential regulation of OR subtypes
in unilateral temporal lobe epilepsy.
Theodore et al.,
1992
Study role of
combined m-/k-OR
binding in temporal
lobe epilepsy.
[
18F]FcyF (m-a n d
k- antagonist) and
H2[
15O]O
(perfusion)
Invasive compartment
model,VT/VOI/n=1 4
Non-significant increased combined
m-/k-OR binding and significant hypoper-
fusion in temporal lobe ipsilateral to
epileptogenic focus.
Suggest that k-OR are not involved in
temporal lobe epilepsy, and therefore
no significant asymmetry in combined
m-/k-OR binding unlike Mayberg et al.,
1991who used a selective m-OR
agonist.
Bartenstein
et al.,1994
Study role of non-
selective OR binding
in temporallobe epilepsy
before and after
surgery.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
and [
18F]FDG
(glucose
metabolism)
Ratio method, BPND/VOI/
n=2pat ientsn=8
controls
Post-operative there was a reduced
diprenorphine binding in the ipsilateral
lateral temporal cortex.
Finding is compatible with downregula-
tion of OR in lateral temporal lobe
after removal of the epileptic focus.
Madar et al.,
1997
Study role of m-OR
(carfentanil) versus
d-OR (naltrindole)
binding in temporal lobe
epilepsy.
[
11C-Me]Nal
(d-antagonist),
[
11C]CAF
(m-agonist) and
[
18F]FDG(glucose
metabolism)
Ratio method, BPND/VOI/
n=1 0
Both m-a n dd-OR binding was increased
in the temporal cortex: m-OR confined
to middle aspect of inferior cortex,
whereas d-OR seen in mid-inferior cortex
to anterior aspect of middle and superior
temporal cortex. Hypometabolism was
more widespread than changes in binding
to either OR type.
Increase in delta receptors suggests
their anticonvulsant action, and the
different regional pattern of receptor
alterations suggest the distinct roles of
different opioid-receptor subtypes in
seizure phenomena.
Hammers et al.,
2007
Investigate OR avail-
ability following spon-
taneous temporal lobe
seizures.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Invasive SA,VT/
SPM +VOI/n=9
patients 2 scans (post-
ictal and interictal), n=1 4
controls 2 scans
Increase in OR availability in the ipsilateral
temporal pole during the postictal scan
compared to control and inter-ictal scan.
There was no reduced OR binding during
the post-ictal scan.
Suggest an association of changes in
endogenous opioid transmission with
spontaneous seizures in temporal lobe
epilepsy.
Koepp et al.,
1998
To localize dynamic
changes in opioid
neurotransmission
associated with partial
(reading) seizures.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Invasive SA,VT/SPM/n=5
patients, n=6cont rols
On activation scans (reading-baseline)
OR-binding significantly lower left
parieto-temporo-occipital cortex in
reading-epilepsy patients compared with
controls.
Opioid-like substances are involved in
the termination of reading-induced
seizures.
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Epilepsy: absence seizure
Bartenstein
et al.,1993
Study role of OR bind-
ing during absence
seizure (ictal).
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
and H2[
15O]O
(perfusion)
Invasive compartment
model, simulation/VOI/
n=8
Increased elimination of diprenorphine
from association cortex.
Suggest that endogenous opioids are
released in the association cortex at
t h et i m eo fs e r i a la b s e n c e s .
Prevett et al.,
1994
Study role of OR bind-
ing in absence seizure
inter-ictally compared
to healthy controls.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Invasive SA,VT/
VOI + SPM/n=8pat ients,
n=8cont rols
No statistical difference between patients
and healthy controls in diprenorphine
binding.
Does not support an overall abnorm-
ality of opioid transmission, but does
not exclude imbalance of receptor
subtypes.
Movement disorders/neurodegeneration
Burn et al.,1995 Study differences in
OR-binding between
akinetic-rigid syndromes.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Radio method, BPND/VOI/
n=8PD ,n=7SN D ,n=6
SRO, n=8cont rols
Parkinson’s diseasewas associated with no
significant difference in binding compared
to controls. Patients with striatonigral
d e g e n e r a t i o ns h o w e dar e d u c e dO Rb i n d -
ing in putamen. Patients with Steele^
Richardson^Olszewski syndrome (SRO)
demonstratedreduced OR bindinginboth
putamen and caudate nucleus. In single
subject analysis, only in some patients the
SRO group showed a reliably reduced
binding.
There are differences in the pattern of
OR binding in the patient groups that
may help to differentiate these
akinetic-rigid syndromes in life.
Cohen et al.,
1998,1999
Role of OR in MPTP-
lesion model of parkin-
sonism in monkeys.
[
18F]FcyF (m-a n d
k-antagonist)
Ratio method, BPND/VOI/
n=4bilat erallesioned ,
n=4 unilateral lesioned,
n=9cont rols
Reduced OR-binding in caudate, anterior
putamen, thalamus and hypothalamus
bilaterally in both uni and bilat lesioned
animals.
Endogenous opiates contribute to the
phenotype of Parkinson’s disease.
Piccini et al.,
1997
To determine whether
the OR system is
involved in levodopa-
induced dyskinesias in
Parkinson’s disease.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Ratio method, SA,VT,
IRF60/VOI+SPM/n=1 3
patients, 6 with dyskinesia
n=1 0cont rols
Significantly reduced striatal and thalamic
opioid binding in dyskinetic, but not in
non-dyskinetic, PD patients. SPM analysis
disclosed additionally decreased cingulate
and frontal cortical binding in dyskinetic
patients.
Confirm that altered opioid transmis-
sion is part of the pathophysiology of
levodopa-induced dyskinesias in
Parkinson’s disease.
Whone et al.,
2004
Investigate OR binding
in DYT1primary torsion
dystonia.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Invasive SA,VT/SPM/n=7
patients, n=1 5cont rols
No difference in diprenorphine binding
was found between DYT1primary torsion
dystonia patients and controls, and no
correlation between the severity of
dystonia and opioid binding.
Aberrant opioid transmission is
unlikely to be present in DYT1primary
torsion dystonia.
von Spiczak
et al.,2 0 0 5
Investigate OR binding
in relation to sensory
and motor symptoms
in restless legs syndrome
(RLS).
[
11C]DPN (m-, k-
and d-a n t a g o n i s t ) )
Invasive SA,VT/SPM/
n=1 5pat ients,n=1 2
controls
No differences in OR binding between
patients and controls. Regional negative
correlations between OR binding and
motor symptoms (thalamus, amygdala,
NC, ACC, insula and orbitofrontal cortex)
and pain scores (orbitofrontal cortex
and ACC).
Suggest a central nervous system
involvement of opioids in the patho-
physiology of RLS. Pain is an underlying
problem in RLS patients and suggested
that motor symptoms in RLS are
secondary to sensory symptoms.
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1997
Opioid neuronal loss is
involved in the degen-
erative process of
Huntington’s disease.
[
11C]DPN (m-, k-
and d-a n t a g o n i s t )
Ratio method, SA/
VOI + SPM/n=5H D ,n=9
controls
Decrease in caudate and putamen OR
binding compared to controls. SPM
revealed additional non-hypothesized
changes in cingulate and frontal cortices
and thalamic areas.
Confirm that altered opioid transmis-
sion is part of the pathophysiology
early Huntington’s disease. SPM
analysis is a viable alternative to
conventional VOI analysis.
Cohen et al.,
2000b
Examine responses in
OR binding to neuro-
degeneration in a lesion
model of the visual
system in monkeys.
[
18F]FcyF (m-a n d ,
k-antagonist)
Invasive, compartment
model,VT/VOI/n=6
lesioned with (4) and
without (2) optical tract
involvement. Scanned
after 2^3 years n=9
controls
The animals with the optic tract lesion
had significantly higher OR binding in the
lateral cortex, cingulate gyrus and poster-
ior putamen. In both lesion groups, OR
binding was reduced in the medial cortex.
Reduced OR binding in medial cortex
are axonal and transneuronal degen-
eration.Visual deprivation leads to
extensive functional changes of neuro-
nal circuitries involving the OR system.
Cohen et al.,
1997
Expected that OR
avidity would be lower
in patients with
Alzheimer’s disease than
in normal controls.
[
18F]FcyF (m-a n dk-
antagonist) and
H2[
15O]O
(perfusion)
Invasive, compartment
model,VT/VOI/n=1 2
patients, n=1 2cont rols
Global grey combined m-/k-OR-binding
and global grey perfusion were found to
be lower in the Alzheimer’s patients com-
pared to controls. A specific hypoperfu-
sion was identified in the parietal cortex,
b u tn os i g n i f i c a n tr e g i o n a lc h a n g e si nO R
binding were found.
Neurodegeneration is the likely under-
lying process responsible for changes in
combined m-/k-OR binding.
Pain: experimental, acute
Zubieta et al.,
2001
Induced muscular
(masseter) pain
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=20 2
scans (placebo and pain)
Sustained pain induced the regional
release of endogenous opioids interacting
with m-OR in a number of cortical and
subcortical brain regions. Associated with
reductions in the sensory and affective
ratings of the pain experience, with dis-
tinct neuroanatomical involvements.
Evidence for the role of the m-OR in
the neurotransmission of the individual
experience of pain.
Bencherifet al.,
2002
Experimental pain
induced by topical
application ofcapsaicin.
[
11C]CAF
(m-agonist)
Ratio method, BPND/SPM/
n=8 2 scans
A pain-related decrease in brain m-OR
binding was observed in the contralateral
thalamus.
The supraspinal m-OR system is
a ct i v a t e db ya c u t ep a i na n dm a yp l a y
a substantial role in pain processing.
Sprenger et al.,
2006a
OR binding studied
during tonic, heat pain.
[
18F]FDPN(m-, d-
and k-antagonist)
Non-invasive Logan plot,
BPND/SPM/n=1 2  2
scans (in and out pain)
Reduction of diprenorphine binding in
limbic and paralimbic brain areas including
the rostral ACC and insula, related to
heat pain.
Direct evidence for the involvement of
rostral ACC in endogenous opioidergic
inhibition of pain.
Zubieta et al.,
2002
Study of gender differ-
ences.I n d u c e dm u s c u -
lar (masseter) pain.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=1 4female,
n=1 4male.Al l 2 scans
(placebo and pain)
Men demonstrated larger magnitudes of
m-OR activation than women in the ante-
rior thalamus, ventral basal ganglia and
amygdala.Women showed a stronger
m-OR activation during pain in the nucleus
accumbens.
M e na n dw o m e n( f o l l i c u l a rp h a s e )
differ in the magnitude and direction
of response of the m-OR system in
distinct brain nuclei.
(continued)
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Smith et al.,
2006
Examination of pain-
related m-OR neuro-
transmission during
low and high estrogen
states in women.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=1 0
females 2s c a n s( l o w
a n dh i g he s t r o g e ns t a t e ) ,
n=8males 1scan
The high-estrogen state was associated
with regional increases in baseline m-OR
binding and greater pain-related activation
of opioid neurotransmission.The latter did
not differ from that obtained in males.
During low-estrogen state, reduced
opioid tone was seen in thalamus, NA and
amygdala, which was associated with
hyperalgesic responses.
Demonstrate a significant role of
estrogen in modulating endogenous
opioid neurotransmission and asso-
ciated psychophysical responses
to pain.
Zubieta et al.,
2003a
Study of gene (COMT)
polymorphism in rela-
tion to pain response
and m-OR activation.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=29 .Al l 2
scans (placebo and pain)
Met158 allele homozygotes for COMT
polymorphism showed diminished m-OR
responses to pain and increased pain
ratings compared to heterozygotes.
Opposite effects were observed in val158
homozygotes.
COMTval158met polymorphism
influences the human experience of
pain and may underlie inter-individual
differences in the adaptation and
responses to pain.
Zubieta et al.,
2005
Analgetic placebo and
m-OR
neurotransmission.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=1 4 3
scans (baseline, pain and
pain+placebo)
Placebo-induced activation of
m-OR-mediated neurotransmission was
observed in left dorsolateral frontal
cortex, rostral ACC, left NA and right
anterior insula, and was paralleled by
lower pain ratings.
Demonstrate thatcognitive factors are
capable of modulating physical and
emotional states through the site-
specific activation of m-OR signalling
Pain: chronic, pathological
Jones et al.,1994 Investigation ofrheu-
matoid arthritis patients
in and out of pain in
relation to OR binding.
[
11C]DPN (m-, d-
and k-antagonist)
Invasive compartment
model,VT/VOI/n=4 2
scans (in and out of pain)
Out of pain was related to a general
increase in diprenorphine binding and
region-specific increases in frontal,
cingulate and temporal cortices and
straight gyrus.
There are substantial increases in
occupancy by endogenous opioid
peptides during inflammatory pain.
Jones et al.,1999 Study OR binding in
patients withtrigeminal
neuralgia pain before
and after thermocoa-
gulation therapy.
[
11C]DPN (m-, d-
and k-antagonist)
Invasive SA,VT/SPM/
n=6 2s c a n s( i na n d
out of pain)
In pain condition compared to out of pain
the regional OR binding was reduced in
frontal, insular, perigenual, mid-cingulate
and inferior parietal cortices, basal ganglia
and thalamus bilaterally.
Suggest an increased occupancy by
endogenous opioid peptides during
trigeminal pain.
Jones et al.,
2004
Study OR binding in
patients with central
neuropathic pain.
[
11C]DPN (m-, d-
and k-antagonist)
Invasive SA,VT/SPM/n=4
patients, n=4cont rols
Less OR binding in a number of cortical
and sub-cortical structures that are
mostly, but not exclusively, within the
medial pain system.
Demonstration of reduced OR-binding
capacity in neurons within the human
nociceptive system in patients with
central neuropathic pain.This may be
a key common factor resulting in
undamped nociceptor activity within
some of the structures that are
predominantly within the medial
nociceptive system.
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2004
Investigate OR binding
in patients with central
post-stroke pain.
[
11C]DPN (m-, d-
and k-antagonist)
Ratio method,
BPND +SA,I R F 60/
SPM +VOI/n=5pat ients,
n=1 2cont rols
Independently of localization of lesion
there was reduced diprenorphine binding
in contralateral thalamus, parietal,
secondary somatosensory, insular and
lateral frontal cortices, and along the
midline in anterior cingulate, posterior
cingulate and midbrain grey matter.
A single lesion associated with a
characteristic pattern of reduced OR
binding within the neural circuitry
processing pain.
Maarrawi et al.,
2007
Investigate the differ-
ences in OR binding
between patients with
central and peripheral
neuropathic pain.
[
11C]DPN (m-, d-
and k-antagonist)
Ratio method, BPND/SPM/
n=7+8pat ientsw ith
peripheral neuropathic+
central post-stroke pain,
n=1 5cont rols
Patients with central post-stroke pain
showed predominantly contralateral
reductions in OR binding, whereas
patients with peripheral neuropathic pain
did not show any lateralized decrease in
OR binding.
Difference in distribution of brain
opioid system changes between
peripheral neuropathic and central
post-stroke pain suggest an opioid loss
or inactivation in the central pain
syndrome, and might explain their
different sensitivity to opiates.
Sprenger et al.,
2006b
Study of OR binding in
patients with cluster
headache,i nb o u tb u t
out of attack.
[
11C]DPN (m-, d-
and k-antagonist)
Invasive SA, IRF60/SPM/
n=7pat ients,n=8
controls
Decreased overall OR binding in the
pineal gland of cluster headache patients
compared to controls. Opioid receptor
availability in the hypothalamus and ACC
depended on the duration of the headache
disorder.
The pathophysiology of cluster head-
ache may relate to opioidergic
dysfunction in circuitries generating
the biological clock.
von Spiczak
et al.,2 0 0 5
Investigate OR binding
in relation to sensory
and motor symptoms
in restless legs syndrome
(RLS).
See above Movement disorder/Neurodegeneration.
Affective states
Zubieta et al.,
2003b
Dynamic changes in
m-OR binding related
to induction of a state
of sadness.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=1 4.Al l 2
measurements (neutral
and sad state)
Sustained sadness compared to neutral
state showed increased m-OR binding in
ACC, pallidum, amygdala and inferior
temporal cortex.Changes in m-OR binding
were correlated to increase in negative
affect ratings.
The responses confirm the role of
the m-OR system in the physiological
regulation of affective experiences in
human.
Kennedy et al.,
2006
Affection: involvement
of m-OR neurotrans-
mission in major
depression and treat-
ment response.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=1 4pat ients,
n=1 4cont rols.Al l 2
measurements: sadness
and neutral state
Differences in m-OR availability between
women with major depression and control
women in neutral state and opposite
responses in opioid neurotransmission
during induced sadness.
The neurotransmission on m-OR
system, which is implicated in stress
responses and emotional regulation,
is altered in patients with major
depression.
Liberzon et al.,
2006
Study of m-OR after
psychological trauma.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/SPM/n=1 6pat ients,
n=1 4( t rauma)+1 5
(non-trauma) controls.
Trauma groups had lower m-OR binding in
amygdale, nucleus accumbens and dorsal
frontal and insular cortices, but higher
m-OR binding in orbitofrontal cortex.
Patients had reduced m-OR in the ACC
compared to both control groups.
There are general trauma-related
responses and specific post-traumatic
changes in the m-OR system.
(continued)
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Addiction
Zubieta et al.,
1996
Opioids are involved in
the reinforcing actions
of cocain.S t u d yo f
cocain craving.
[
11C]CAF
(m-agonist)
Ratio method, BPND/VOI/
n=10 patients 2s c a n s ,
n=7cont rols
Mu opioid binding was increased in several
brain regions of the cocaine addicts
studied1^4 days after last use of cocaine
and persisted after 4 weeks. Binding was
positively correlated with the severity of
cocaine craving experienced at the time.
Demonstrate the involvement of the
endogenous OR system in cocaine
dependence and cocaine craving.
Gorelick et al.,
2005
Study m-OR binding in
cocaine abstinence and
in relation to craving
over an extended time
period.
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/VOI/n=1 7
patients 3s c a n s( 1 d a y ,
1w ee kand1 2w ee ks ) ,
n=1 6cont rols.
After1day of abstince m-OR binding was
increased in several areas of the FC and
in ACC.FC, ACC and lateral temporal
cortex. After12 weeks of abstinence
increased binding was only seen in
anterior FC and ACC. Self-reported
cocaine craving was associated with m-OR
in several brain regions until after1week
of abstincence. (No reported craving at
12 weeks)
Mixed pattern of normalizing and
persistent increased m-OR binding
suggests that there might be both
state and trait relationships.
Scott et al.,
2007b
Effects of nicotine from
smoking cigarettes in
humans on
m -opioidergic
(and dopaminergic)
neurotransmission.
[
11C]CAF
(m-agonist) and
[
11C]raclopride
(dopamine-D2
receptor
antagonist)
Non-invasive Logan plot,
BPND/SPM/n=6
smokers  2m e a s u r e -
ments in one scan: before
and during smoking, n=6
non-smokers
Smokers have lower m-OR binding during
denicotinized cigarette condition
compared to non-smokers in ACC,
thalamus, ventral basal ganglia and
amygdala.These reductions were reversed
during smoking in thalamus, ventral basal
ganglia and amygdale. A reduced binding
was observed in parts of the ACC during
smoking. Dopamine neurotransmission
was activated in the ventral basal ganglia.
Smoking is related to changes in m-OR
availability and is paralleled by changes
in dopamine neurotransmission.
Bencherifet al.,
2004
Study relationship
between alcohol
craving and m-OR in
alcohol-dependent
subjects.
[
11C]CAF
(m-agonist)
Ratio method, BPND/SPM/
n=8pat ients,n=8
controls
Alcohol-dependent subjects showed
association with higher craving and lower
m-OR binding compared with control
subjects in right dorsal lateral frontal
cortex, the right anterior frontal cortex,
and right parietal cortex.
There is a functional relationship
between alcohol craving, mood and
m-OR binding in specific brain regions
of recently abstinent, alcohol-
dependent men.
Heinz et al.,
2005
Study of m-OR changes
afteralcholism detoxifi-
cation and in relation
to craving
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/VOI+SPM/n=25
patients (n=12 rescanned
after 5 weeks), n=1 0
controls
After1^3 weeks of abstinence m-OR
binding was increased in the ventral
striatum compared to controls and
remained elevated after 5 weeks. Higher
m-OR binding correlated positively with
intensity of alcohol craving.
There is increased m-OR binding in
alcohol detoxified patients within
a neural network that has been
associated with drive states and
drug craving.
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2005
Study of pharmacoki-
netics and m-OR
occupancy ofnalmefene
after single and
repeated dosing over
7d a y s .
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/VOI/n=1 2 3
scans, all before drug and
2 each at 3, 26, 50 or 74h
after single drug intake,
and all after 7 days of
repeated dosing.
High nalmefene occupancy (83^100%)
persisted at 26h after the dosings, and
decline in the occupancy was clearly
slower than the decline in the plasma
concentration of nalmefene or
metabolites.
The slow dissociation of drug from
m-OR suggest that a high receptor
occupancy can be maintained when
nalmefene is taken once daily.
Kling et al., 2000 Investigation of metha-
done treatment in
heroin addicts.
[
18F]FcyF (m-a n d
k-antagonist)
Invasive compartment
model,VT/VOI/n=1 4
patients, n=1 4cont rols
Combined m-/k-OR binding in thalamus,
amygdala, caudate, anterior cingulate
cortex and putamen was significantly
reduced (19^32%). Methadone plasma
levels correlated to receptor occupancy
in caudate and putamen.
Lower levels of m-/k-OR binding may
be related to receptor occupancy with
methadone and that significant
numbers of OR may be available to
function in their normal physiological
roles.
Melichar et al.,
2005
Study relationship
between methadone
dose and OR in heroin
dependent patients
[
11C]DPN (m-, d-
and k-antagonist)
Invasive SA,VT/VOI/n=8
patients, n=8cont rols+
animal studies
No difference in diprenorphine binding
was found between the groups, with no
relationship between methadone dose and
occupancy either given chronically in
humans or acutely in rats.
Suggest high efficacy of methadone at
very low levels of OR occupancy.
Greenwald
et al.,2 0 0 3
Study of heroin-
dependence and bupre-
norphine treatment
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/VOI/n=1 4pat ients.
(5 completed all 4 scans
at 0, 2,16 and 32mg
buprenorphine).
m-OR availability decreases were
negatively correlated with BUP plasma
level and positively correlated with
questionnaire-based opioid withdrawal
symptoms.Over 90% receptor occupancy
at doses of 32mg buprenorphine.
Suggest that high-dose buprenorphine
maintenance produces near-maximal
m-OR occupation and m-OR availability
correlates well with plasma levels.
Greenwald
et al.,2 0 0 7
Study of buprenorphine
duration of action
[
11C]CAF
(m-agonist)
Non-invasive Logan plot,
BPND/VOI/n=1 0  4
scans (4, 28, 52 and 76h
after last buprenorphine
dose)
Whole-brain m-OR availability increased
from 30%, 54%, 67% to 82% after 4, 28,
52 and 76h, respectively, of last buprenor-
phine dose. m-OR binding correlated
with plasma concentration, withdrawal
symptoms and hydromorphone blockade.
The m-OR availability predicts changes
in pharmacokinetic and pharmako-
dynamic measures, and  50^60%
receptor occupancy of buprenorphine
is required for adequate withdrawal
symptom suppression.
Eating disorder
Bencherifet al.,
2005
Study m-OR in bulimia
nervosa as the OR
system has been impli-
cated in feeding
behaviour.
[
11C]CAF
(m-agonist)
Ratio method, BPND/SPM/
n=8pat ients,n=8
controls
m-OR binding in the left insular cortex
was less in bulimic subjects than in
controls and correlated negatively with
recent fasting behaviour.
m-OR binding in the insula may be
important in the pathogenesis or
maintenance of the self-perpetuating
behavioural cycle of bulimic subjects.
The consensus nomenclature for PETreceptor binding has been used throughout the table (Innis et al., 2007).
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5and graphical models. There is no consensus on the correct
approach and it would represent an improvement to report
the parametric values and changes in absolute values in
addition to statistical maps.
Before calculating a voxel-wise statistical analysis of
whole brain, spatial smoothing is routinely applied to
reduce the effect of interindividual anatomic variability and
to improve statistical power. The spatial smoothing affects
the statistical maps (t-maps) and may result in spatial
inaccuracy, which can be corrected for (Reimold et al.,
2006). These authors suggested use of the mask contrast
images (in SPM) to avoid the artifacts and improve the
spatial precision. MR-based correction of PET gray matter
distribution permits an improved determination of the true
radioactivity concentration and reduces partial volume
effect mixed tissue sampling errors (Meltzer et al., 1996).
The volume of abnormal brains may be different to that of
brains of healthy individuals and thus require a correction
for partial volume effects. One should also be aware of
the possibility that different results between studies may be
dependent on the individual scanner systems used, which
undoubtedly have different sensitivities and resolutions.
Opioid receptor studies in humans
The first successful PET study with an opioid receptor
ligand was performed in 1985 using the m-OR agonist
[
11C]CAF (Frost et al., 1985). Two years later, [
11C]DPN
was introduced as a non-selective OR-antagonist for
PET (Lever et al., 1987). Studies of the brain opioid
receptor system using PET have been applied for neuro-
chemical mapping and for studies of pain, emotion, drug
addiction, movement disorders, neurodegeneration and
epilepsy. Based on the last decade of research, [
11C]DPN,
[
11C]CAF and [
18F]FCyF are the most widely applied
tracers, followed by [
18F]FDPN and the d-OR-selective
ligand [
11C]MeNTl (Fig. 1). Although being one of the
two PET tracers with a pronounced subclass selectivity
the quantification of [
11C]MeNTl binding is difficult due
to a near irreversible binding (Smith et al., 1999).
Most studies use static depiction of the receptor binding
in repeated measurements in the same individuals and/or in
comparison to healthy volunteers. In later years, dynamic
changes in OR availability (opioid activation) have been
measured between different states. Table 1 summarizes
the clinical studies on PET-imaging of ORs in the CNS
reported so far.
Neurochemical mapping
PET offers the possibility to study in vivo anatomy and
function of neurochemical systems of the whole brain with
information on the regional and the inter-individual
characteristics. This makes studies of the receptor systems
in healthy individuals appealing. Studies of the opioidergic
mechanisms in the brain have been extensively performed
in animal models. Although several interspecies differences
among mammals such as mouse, rat, guinea pig, rabbit and
human have been described for distinct brain areas (Maurer
et al., 1983; Zagon et al., 1990), it has been very limited
research on the anatomy and function of the opioidergic
system of the human brain. An extrapolation to humans of
a finding in other mammals may not always be applicable.
For example in the rat, which probably represents the most
widely used laboratory animal and where the distribution of
the three principal opioid receptors has been extensively
studied in the brain (e.g. Mansour et al., 1995), the
cerebellum typically is devoid of opioid receptors. PET was
therefore used in a detailed study of the cerebellum using
[
11C]DPN and individual MRI in parallel with in vitro
receptor autoradiography and mRNA expression in post-
mortem human and rat brain (Schadrack et al., 1999).
[
11C]DPN in PET demonstrated low to intermediate OR
binding in the human cerebellum. The human in vitro data
showed a differential subtype pattern with pronounced
levels of m-OR and lower levels of k-OR, but no detectable
d-OR. The specific binding corresponded to the level of
the respective OR-expression as measured by quantification
of mRNA.
Jones et al. (1991) described the in vivo distribution
of [
11C]DPN binding in man in relation to the medial
(functional subdivision of brain areas mediating the
affective-motivational components in pain perception)
and lateral pain systems (brain areas mediating sensory-
discriminative components in pain perception). In general,
high levels of opioid receptor binding was seen in the
cortical projections of the medial pain system (cingulate
and frontal cortex) and a focal lower binding was observed
in the primary sensorimotor cortex, a part of the lateral
pain system. A more detailed and complementary study
using [
18F]FDPN PET and coregistered individual MRI
revealed a high opioid receptor binding in the secondary
sensory cortex and the posterior part of insula, both parts
of the lateral pain system (Baumgartner et al., 2006). The
lateral pain system comprises apparently areas with high
and low opioid receptor availability. Baumgartner et al.
(2006) added in the same study a factor analysis of inter-
individual variability in regional OR binding and identified
four factors explaining 88% of the variance. Each factor
consisted of different sets of brain regions and the
authors speculated that each factor may display functional
entities.
A detailed study of the OR binding in the human
cingulate gyrus combining [
11C]DPN PET with individual
MRI supported of high binding levels (Vogt et al., 1995).
It was also shown that a striking heterogeneity of opioid
receptor binding exists on the medial cortical surface with
a higher availability in the anterior as compared to mid-
cingulate cortex. The above-described approaches do not
only describe a pattern of regional binding, but also suggest
a reason for some of the actions of opiate compounds and
may provide clues into the functional subdivisions and
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above studies is the use of non-selective antagonists as
PET-ligands, and therefore cannot differentiate between the
regional distribution of m-, k- and d-ORs. The differences
or lack of differences in receptor binding, Bavail, are a sum
of binding to two or more OR subtypes, e.g. increased Bavail
for m-OR and decreased Bavail for d-OR may result in a net
of no differences.
In the first human opioid PET study using the m-selective
agonist [
11C]CAF, Frost et al. (1985) described high
concentrations of ORs in the basal ganglia and thalamus,
intermediate concentrations in the frontal and parietal
cerebral cortex, and low concentrations in the cerebellum
and occipital cortex. The selective d-OR antagonist
[
11C-methyl]naltrindole (
11C-MeNal) showed a high bind-
ing availability in the frontal cortex and putamen, lower
levels in thalamus and an absence of specific binding in the
human cerebellum (Smith et al., 1999). Recently, a detailed
evaluation of [
11C]GR103545 as a PET tracer for k-OR in
non-human primates was reported (Talbot et al., 2005).
These investigators found a regional pattern of specific
binding of [
11C]GR103545 in baboons which agrees with
the regional distribution of k-ORs in humans primates
(Hiller and Fan, 1996) with a high binding in cingulate
cortex, striatum, frontal cortex, temporal cortex and
parietal cortex; intermediate levels were found in thalamus
and medial temporal lobe, and low levels in brainstem and
occipital cortex. No human studies have been published
so far with a PET-tracer with high selectivity for the k-OR.
Both age and gender may be important variables to
consider in the interpretation of investigations of human
function in which the opioid system plays a role. m-OR
binding has been shown to increase with age in neocortical
areas and caudate putamen, while women show a higher m-
OR binding than that found in men in the thalamus,
amygdala and cerebellum (Zubieta et al., 1999). However,
in vivo m-OR binding in thalamus and amygdala declined in
postmenopausal women to levels below those of men. The
findings of Cohen et al. (2000a) using the m-/k-antagonist
[
18F]FCyF showed in accordance a lower thalamic OR
binding in postmenopausal women. These changes observed
in postmenopausal women suggest that the hormonal
milieu representative of healthy adults is capable of
modulating the OR neurochemical system, at least in
some brain regions. The sex differences in m-OR binding
during the female reproductive years may reflect early,
gender-specific ontogenetic factors. Another study has also
shown that there are no significant categorical differences in
m-OR binding between phases of the menstrual cycle (Smith
et al., 1998). However, when the receptor-binding data were
compared with circulating levels of gonadal steroids
separately for each phase of the cycle, several significant
correlations emerged. The circulating levels of estradiol
in the follicular phase, but not luteal phase, influenced
OR binding in amygdala and hypothalamus, presumably
reflecting an increased central opioid tone. The m-OR
binding in the amygdala had a modulatory effect on
GnRH release pulsatility. This finding is interesting, as
the amygdala is associated with emotional responses and
memory, providing a neurochemical link between repro-
ductive and emotional function.
There is a strong interest in the discovery of genes
that are related to individual differences in the processing
of endogenously produced opioid receptor ligands
and receptors. The only study so far investigating the
association between genotype and m-OR phenotype was
directed towards the polymorphism of catechol-O-methyl-
transferase (COMT), the enzyme responsible for the
metabolic conversion of catecholamines (dopaminergic
and adrenergic/noradrenergic neurotransmission). The effi-
ciency of COMT is dependent on the presence of the
combination of valine (val) or methionine (met) in the
active site (amino acid 157–158). The three combinations
val-val, val-met or met-met allowed identification of an
effect of the COMT val
158met genotype on baseline binding
of the m-OR selective agonist [
11C]CAF in the thalamus and
ventral basal ganglia (Zubieta et al., 2003a). The met/met
group showed a regional higher m-receptor binding at
baseline in the basal ganglia compared to the met/val group.
A lower m-receptor binding was seen in thalamus, nucleus
accumbens and amygdala in the val/val group as compared
to the met/val group. The differences in binding are likely
secondary compensatory changes within the OR system
in response to the COMT enzyme activity. Functional
relevancies of genotype to pain perception are discussed
below (see ‘Experimental, Acute Pain’ section).
Epilepsy
The first clinical PET study with an OR ligand focussed on
epilepsy was reported by Frost et al. (1988), demonstrating
an increased m-OR binding of [
11C]CAF in temporal lobe
epilepsy. An inverse relationship to the well-known
interictal hypometabolism in the epileptogenic temporal
lobe was shown. In contrast, no such asymmetry was
detectable using the non-selective OR ligand [
11C]DPN
(Mayberg et al., 1991), indicating that the subtypes
(m, k and/or d) are regulated differently or present different
availability to the PET ligand in the inter-ictal period.
Similarly, there was no overall asymmetry of binding of
[
18F]FCyF (m- and k-OR) in patients with temporal lobe
epilepsy (Theodore et al., 1992). Studies using the d-OR
ligand [
11C-Me]Nal (Madar et al., 1996, 1997) showed
increased d-OR availability in the ipsilateral temporal lobe,
but with a different regional pattern than the m-OR binding
of [
11C]CAF. The latter was confined to the middle aspect
of the inferior temporal cortex, whereas binding of d-OR
increased in the mid-inferior and anterior aspect of the
middle and superior temporal cortex. Both d- and m-OR
endogenous ligands are thought to play a role in the
tonic anticonvulsive mechanism that limits the spread of
electrical activity from an epileptogenic focus and the above
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quantifying the receptor binding at a single time point,
as all the above studies do, does not reveal any dynamic
changes in neurotransmission. In a longitudinal study,
Bartenstein et al. (1994) compared [
11C]DPN binding
before and after hippocampectomy, and a downregulation
of ORs after removal of the epileptic focus was found.
No further studies have been conducted to confirm this
study, which involved only two patients. OR measurements
during a focal epileptic seizure have been performed in
patients with reading-induced seizures, using [
11C]DPN.
During a seizure OR binding was reduced in the left
parieto-temporo-occipital cortex, which was related to
apparent release of endogenous opioid peptides (Koepp
et al., 1998). Although the mechanisms are not clear, this
finding supports the hypothesis that opioid substances may
be involved in the termination of seizures. A dynamic study
with [
11C]DPN suggested that endogenous opioids are
released in the association cortex during absence seizures
(Bartenstein et al., 1993). A follow-up study to identify
potential changes interictally did not show any overall
differences in [
11C]DPN binding between control subjects
and patients with childhood and juvenile absence epilepsy
(Prevett et al., 1994), suggesting there is no overall abnor-
mality of ORs in this condition. A very recent study
investigated the OR binding ([
11C]DPN) in the post-ictal
period (1.5–21h) and revealed an increased overall OR
availability in the temporal lobe ipsilateral to the ictal focus
(Hammers et al., 2007). The OR binding returned to
normal levels in the interictal period (6–56 days).
In summary, there is an increased availability of m- and
d-OR at the side of ictus in temporal lobe epilepsy
interictally, but there is no identifiable asymmetry seen
when using ligands binding to the k-OR through
non-selective m/d/k or m/k PET-ligands. Studies with a
k-OR-selective tracer to clearly identify potential changes
to the availability of this receptor are still to be performed.
The focal displacement of OR-ligand binding during a
seizure in reading-induced seizures (Koepp et al., 1998) and
absences (Bartenstein et al., 1993) support the prevailing
opinion that endogenous opioids are released following
partial and generalized tonic–clonic seizures (Bajorek et al.,
1986). It has also been suggested that endogenous opioids
contribute to the postictal rise in seizure threshold
(Hammers et al., 2007). If this is true, then there must be
a significant upregulation of available ORs to explain the
increased overall m/d/k-OR binding in the post-ictal period
(Hammers et al., 2007) and increased binding to m- and
d-ORs interictally (Mayberg et al., 1991; Madar et al., 1997;
Frost, 1998). An alternative explanation might be that there
is a reduced inter-/post-ictal endogenous opioid tone
following the phasic release during an ictus. In addition
to OR-subtype selectivity, the pharmacological properties of
the ligands (agonist, antagonist) may influence the different
results of the studies, which all use a limited number
of patients (n=2–14). In general, the opioids are believed
to exert anticonvulsive effects, but proconvulsive effects are
still debated within specific brain regions (e.g. disinhibition
in hippocampus) or as a result of changed cellular function
after repetitive opioid release (Tortella, 1988).
Movement disorders/neurodegenerative
diseases
Movement disorders
The basal ganglia consist of four main nuclei (the striatum,
the globus pallidus, the subthalamic nucleus and the
substantia nigra), which provide a major link between
the thalamus and the cerebral cortex. These nuclei receive
multimodal input from all sensory systems, providing
a gating station for continuous sensory information,
including pain. Dysfunctions of the basal ganglia result in
movement disorders, indicating an important role in motor
control. Endogenous opioid peptides are found in high
concentrations in the basal ganglia and are thought to play
a role in the regulation of motor function (Haber and
Watson, 1985). Exogenously administered opioid agonists
are associated with an increase in motor activity (Austin
and Kalivas, 1990). Abnormal opioid transmission has also
been implicated in several movement disorders, including
levodopa-induced dyskinesias in Parkinsons’s disease,
chorea in Huntington’s disease, neuroleptic-induced tardive
dyskinesia/dystonia and tics in Tourette’s syndrome
(Brooks et al., 2000).
The clinical differentiation of Parkinson’s disease from
the striatonigral degeneration type of multiple system
atrophy and Steele–Richardson–Olszewski (SRO)-syndrome
is challenging. A study concluded that there are differences
in the pattern of OR binding in the striatum of Parkinson’s
disease, striatonigral degeneration and SRO-syndrome
patients, as determined by [
11C]DPN (Burn et al., 1995).
The different binding patterns between the patient groups
indicate a potential of opioid-PET to provide a differential
diagnosis of these akinetic-rigid syndromes. However, in
the single-subject analysis, it was only some patients in the
SRO group that showed a reliable difference and revealed
a limited potential clinical application. Patients with
Parkinson’s disease constituted one of the groups that did
not show any significant changes in OR binding compared
to the healthy controls. These results therefore contradicted
those of Cohen et al. (1998, 1999), who used a lesion
model in rhesus monkeys that damaged the nigrostriatal
system (injecting MPTP intravenously and intraarterially)
in order to monitor changes in the OR binding at an early
preclinical stage of Parkinson’s disease. The availability
of m–k opioid receptors was shown by means of [
18F]FCyF
binding, to be reduced by 30–35% in the basal ganglia,
thalamus and amygdala. One interpretation might be that,
regarding ORs, the MPTP lesion model is not relevant
for Parkinson’s disease. However, different phenotypes of
Parkinson’s disease can be reflected at the level of OR
transmitters. A significantly reduced binding of [
11C]DPN
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increased binding in frontal cortex were found in
Parkinson’s patients with levodopa-induced dyskinesia but
not in non-dyskinetic Parkinson’s patients (Piccini et al.,
1997). These findings suggest that Parkinson’s disease with
levodopa-induced dyskinesia is associated with a derange-
ment of basal ganglia opioid transmission that may
contribute to the overactivity of basal ganglia-frontal
projections. It would be tempting to assign the changes in
OR binding to a common mechanism underlying all
disorders of dyskinesia. The hypothesis of a common
mechanism in dyskinesia, however, was not supported by
the finding that primary torsion dystonia (inherited type
DYT1) was not associated with any abnormal binding of
the non-selective antagonist opioid [
11C]DPN compared
to healthy controls (Whone et al., 2004).
The pathophysiology of primary restless legs syndrome
remains unknown. Dopamine treatment is symptomatically
effective (Hening et al., 1999), but imaging studies have not
given conclusive results of any consistent functional changes
in the nigrostriatal dopaminergic system. A possible role of
opioidergic dysfunction in the pathophysiology of this
syndrome was investigated using [
11C]DPN (von Spiczak
et al., 2005) and a relation between symptoms and receptor
binding indicated an involvement of opioids. The opioid
system may be involved both as part of the aberrant pain
perception of the restless legs syndrome and as a disturbed
balance of dopamine-opioid inputs to brain regions
involved in motor actions.
In the degeneration due to Huntington’s disease (HD) an
involvement of the opioid system is indicated by a reduced
concentration of enkephalin and dynorphin in pallidal,
striatal and nigral regions, in addition to a loss of ORs
in the basal ganglia (Seizinger et al., 1986; Gulya, 1990).
A[
11C]DPN-PET study supports these findings and
demonstrated a decreased OR binding in the caudate and
putamen in HD (Weeks et al., 1997). Atrophy of the
caudate and putamen is well known, and number of cells
and reduction in volume (neurodegeneration) is a possible
explanation for the reduced binding. An exploratory
analytical approach in the same study using SPM detected
additional OR binding increases in brain areas that were
not predicted a priori (cingulate, thalamus and frontal
cortex). The involvement of these brain areas is not
unlikely, but the non-selective binding of [
11C]DPN to
different OR subtypes with the resulting lack of information
on the contribution of individual receptor subtypes to
tracer uptake makes further interpretation difficult.
In an experimental lesion-model of the optical tract
in monkeys, changes in the binding of [
18F]FCyF (m- and
k-OR) were studied 2–3 years after performing the lesions
(Cohen et al., 2000b). The animals underwent either callosal
transection only (split), or callosal and unilateral optic tract
transection (tract and split). Cohen et al. (2000b) reported
a reduced [
18F]FCyF binding in the medial cortex for
both groups, suggesting an axonal and transneuronal
degeneration. In the tract and split group there was,
additionally, a significant bilateral increase in OR binding
in the lateral cortex, cingulate and posterior putamen. The
increased binding reflects functional changes within the
OR system, in response to the visual deprivation, and
demonstrates adaptive mechanisms that may take place
in neurodegenerative disorders, e.g. non-hypothesized
increased binding in the thalamus as well as cingulate and
frontal cortices in patients with HD (Weeks et al., 1997).
Dementia
An involvement of the OR system in Alzheimer’s disease
was shown in a study with [
18F]FCyF (m- and k-OR)
revealing a lower global binding in Alzheimer’s cases, but
failed to demonstrate regional specificity in the ligand
binding, which was interpreted as a general neurodegenera-
tion and no specific involvement of the OR-system (Cohen
et al., 1997).
Pain
Experimental, acute pain
A decrease in OR availability related to acute pain has
so far been demonstrated by three independent research
groups, each using different experimental paradigms
(muscle, capsaicin and heat pain) (Zubieta et al., 2001;
Bencherif et al., 2002; Sprenger et al., 2006a). Changes in
OR binding in the insular cortex, the amygdala, the
thalamus and the nucleus accumbens were confirmed
using both the m-OR selective ligand [
11C]CAF (Zubieta
et al., 2001; Bencherif et al., 2002) and the non-selective
ligand [
11C]DPN (Sprenger et al., 2006a). Unlike the two
first studies, which activated the dorsal part of the anterior
cingulate cortex (ACC), the study of Sprenger et al.
included an opioid activation of the rostral/perigenual
part of the ACC. The rostral part of the ACC is frequently
activated in modulation of pain and analgesia (Willoch
et al., 2003). The experimental setup of stimulus/activation
and the choice of tracer may explain the divergency.
Interestingly, the effect of placebo on m-OR-mediated
neurotransmission was seen in the perigenual part of the
ACC together with significant effects in the dorsolateral
frontal cortex, anterior insula and nucleus accumbens
(Zubieta et al., 2005). The study of opioid involvement in
the effect of placebo demonstrates that cognitive factors are
capable of modulating physical and emotional states
through a site-specific activation of the m-signalling in
the brain. It has also been shown that the activation of the
m-OR system was associated with reductions in the
sensory and affective ratings of the pain experience, with
distinct neuroanatomical involvements (Zubieta et al., 2001;
Bencherif et al., 2002). These data demonstrate the central
role of m-ORs and their endogenous ligands in the
regulation of sensory and affective components of the
pain experience.
Imaging opioid receptors in the CNS Brain (2008),131, 1171^1196 1189As mentioned earlier, men and women have region-
specific differences in OR binding at rest, but also differ in
their OR-mediated responses in distinct brain areas at
matched levels of perceived pain intensity (Zubieta et al.,
2002). Recently, the specific effect of estradiol on opioid
neurotransmission in women was investigated (Smith et al.,
2006). The authors concluded that a low-estradiol, low-
progesterone condition is associated with a pain vulner-
ability state by a reduction in endogenous opioid system
function, possibly through b-endorphin-mediated mecha-
nisms. Genotype influences the opioid neurotransmission
to pain stressors as well. As referred to above in section
‘Neurochemical mapping’ heterozygote and homozygote
individuals have significant different regional OR binding at
baseline (Zubieta et al., 2003a). In the same study, it was
shown that the COMT polymorphism (met/met, met/val or
val/val) influenced the m-opioid responses to pain stimula-
tion. The met/met individuals had lower magnitudes of
m-opioid system activation and higher pain ratings, and
opposite, the val/val individuals had the higher magnitude
of opioid activation and lower pain ratings.
Chronic, pathological pain
Opioid analgesics are used extensively in the management
of pain, and the endogenous opioid receptor system takes
part in the pain processing in the CNS. The first study
investigating changes to the OR-availability in relation to
pain was published by Jones et al. (1994). Patients with
rheumatoid arthritis showed, during a period of inflamma-
tory pain, lower binding compared to a pain-free period,
particularly in orbitofrontal cortex, anterior insula, amyg-
dala and anterior putamen, but also in periventricular grey,
thalamus, and temporal, frontal and anterior cingulate
cortices. These findings were interpreted as an increased
occupancy by endogenous opioid peptides during inflam-
matory pain (Jones et al., 1994). The change in receptor
binding did not take place acutely, but after a substantial
interval between first and second PET scan. Therefore,
the changes observed could just as well have been due to
slower regulating mechanisms, e.g. down-regulation.
Studies on central neuropathic pain (Willoch et al., 1999,
2004; Jones et al., 2004) demonstrated reductions in
[
11C]DPN binding predominantly within the medial pain
system, but also the lateral pain system. These changes
in binding could not be accounted for by the cerebral
lesions shown by CT or MRI, and may instead reflect an
undamped nociceptor activity within the pain-processing
network. The information of a single focal lesion inducing
widespread changes may represent an important step
towards an understanding of the pathophysiology of central
pain (Casey, 2004; Willloch et al., 2004). Maarrawi et al.
(2007) demonstrated that patients with central neuropathic
pain have predominantly contralateral reductions in ORs,
whereas patients with peripheral neuropathic pain do not
show lateralized OR binding. The study supports the idea
that pain syndromes may have, if not archetypical binding
patterns, then at least different neurochemical mechanisms.
The difference between the patients with central and
peripheral neuropathic pain is reflected in their different
sensitivity to opioid analgesia. Maladaptive plasticity within
the opioidergic neurotransmission system may be a part of
the pathology of central pain. An increase in the occurrence
of direct excitatory effects in response to chronic increased
opioid neuronal tonus could contribute to the appearance
of paradoxical opioid-mediated pain, hyperalgesia and
allodynia (Varga et al., 2003).
In a recent study, it was demonstrated that a focal
decrease in OR binding occurred in the pineal gland in
patients with cluster headache during a headache period,
but not during an acute attack (Sprenger et al., 2006b).
The OR availability in the hypothalamus and cingulate
cortex was found to be dependent on the duration of the
patient’s cluster headache. Overall, the findings indicate
that opioidergic mechanisms are involved in the pathophy-
siology of cluster headache. Interestingly, the changes in
opioidergic neurotransmission had another pattern than in
neuropathic and inflammatory pain. This may imply that
a different regulation/dysregulation of opioidergic signalling
may take place according to each specific pain disease,
and that there is not merely an unspecific recruitment of
the opioid system within the pain-processing network in all
pain pictures.
These PET studies confirm the central role of the OR
system in pain and analgesia and show that there are
specific differences due to genetic variation and gender,
and the participation of the OR system in the processing
and perception of and coping with pain may be dependent
on individual constitution. Finally, the OR system does not
seem to respond with a common neurochemical activation
pattern to all kinds of pain, but may express or take part
in the adaption and/or pathophysiology of pain specific for
each pain disease/entity.
Affective states
It has been suggested that activation of the m-OR has a
suppressive effect on emotional reactivity, with the opposite
effect being found for the d-OR (Filliol et al., 2000).
This notion is in accordance with an involvement of the
m-OR-mediated neurotransmission in the suppression of
the affective qualities of a pain stimulus. Using a similar
scanning paradigm as in the studies of acute experimental
pain, the effect of sustained sadness versus neutral
emotional states on [
11C]CAF binding has been investigated
(Zubieta et al., 2003b). The self-induction of a sustained
sadness state was associated with significant reductions
in m-OR-mediated neurotransmission (increased OR avail-
ability) in the rostral ACC, ventral pallidum, amygdala
and inferior temporal cortex. These brain areas are part
of the neural circuits representing and integrating emo-
tional information. A more recent study demonstrated
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in patients with major depression disorder compared to
healthy controls (Kennedy et al., 2006). Larger reductions
in OR binding during sadness were obtained in the patient
group in the anterior insula, thalamus, ventral basal ganglia
and amygdala, and larger increases in OR binding was
observed in the control group in the ACC, ventral basal
ganglia, hypothalamus and amygdala.
In a study of psychological trauma, war veterans exposed
to trauma both with and without posttraumatic stress
disorder had lower OR binding in the insula, ventral basal
ganglia, dorsal frontal cortex and amygdala as well as
increased binding in the orbitofrontal cortex, compared
to healthy controls. This response may have a general
adaptive role in trauma with changes in endogenous opioid
peptide release and a subsequent up- or downregulation
of the OR. The group with posttraumatic stress disorder
had additionally reduced OR binding in the ACC compared
to the other groups, which may represent specific changes
associated with the stress disorder.
Eating disorders
Disorders related to eating behaviour include bulimia
nervosa. This is characterized by a behavioural cycle charac-
terized in restricted food consumption, bingeing and
vomiting, thus sharing phenomenological similarity with
the addiction disorders. The sole study on this topic carried
out so far demonstrated a relative decrease in m-OR binding
of [
11C]CAF in the left temporoinsular cortex, and the
changes in binding correlated inversely with the frequency
of fasting behaviour in the prior month (Bencherif et al.,
2005). The insula is the primary part of the cortex process-
ing gustatory sensory information (Frey and Petrides, 1999)
and anticipation and reward of eating, and is most
consistently activated in anxiety neuroimaging studies
(Malizia, 1999).
Addiction
Stimulation of the m-OR is mainly responsible for the
reinforcing effects of opioid drugs, although d-ORs may
also contribute (Self and Stein, 1992). The k-OR is also
involved in the responses to addictive drugs, particularly
cocaine, but also to opiates (for recent reviews see
Prisinzano et al., 2005; Henriksen et al., 2006). Different
drugs of abuse stimulate dopamine release in the ventral
striatum, which includes the nucleus accumbens. Striatal
dopamine release is stimulated by m-OR activation and
inhibited by striatal k-OR activation. It has been hypothe-
sized the latter may thus represent a homeostatic mecha-
nism that limits drug-induced dopamine release in the
ventral striatum (Prisinzano et al., 2005 and references cited
therein). An elevated k-OR-mediated signalling may persist
during the phase of withdrawal from the drug and thus
contribute to dysphoric mood states and thus increase the
relapse risk. In vivo brain imaging with k-OR-selective
radioligands will allow the assessment of the opioidergic
system in drug-dependent humans, to examine the psycho-
logical correlates of its functional state, and to develop new
strategies to target drug effects and alleviate drug addiction.
An involvement of the endogenous opioid system after
cocaine use was shown in subjects with current cocaine
abuse/dependence (Zubieta et al., 1996; Gorelick et al.,
2005). After 1–4 days of cocaine abstinence, m-OR binding
of [
11C]CAF was increased in several brain regions,
including frontal cortex, lateral temporal cortex and ACC.
The increased binding correlated positively with self-
reported cocaine craving. Twelve weeks after abstinence,
the binding remained increased in the anterior frontal and
anterior cingulate cortex, but returned to normal in the
other brain regions. The mixed pattern suggests that there
might be both state- and trait mechanisms, the state-
dependent changes reflected in OR-binding returning to
normal levels, and apparent trait-dependent OR-binding
differences identified in the ACC. It would be interesting
to examine the relationship between the trait-dependent,
elevated m-OR binding in the ACC and long-term clinical
phenomena, such as vulnerability to craving and relapse.
Some of the effects of tobacco consumption are mediated
through nicotine, which activates opioid neurotransmission
(Scott et al., 2007b). At baseline, cigarette smokers had a
reduced m-OR binding in the ACC, thalamus, ventral basal
ganglia and amygdala, which were (except in the ACC)
reversed to normal during smoking. The observed reduced
binding in the de-nicotined state was unexpected, but may
represent a state of stress-related increased opioid tonus.
Several studies provide support for an association between
alcohol dependence and CNS dopaminergic function
(for reviews see: Noble, 1996; Soderpalm et al., 2000)
as well as opioidergic function (Herz, 1997). PET studies of
OR binding have shown very small group differences
between alcoholic patients and healthy controls (Bencherif
et al., 2004; Heinz et al., 2005). Heinz et al. (2005) identified
an increased availability of m-ORs in the ventral striatum
(including the nucleus accumbens), in alcoholic patients
(compared with healthy controls) after 1–3 weeks of abstin-
ence, which persisted 5 weeks later. Interestingly, alcohol
craving correlated positively with m-OR-binding levels in
striatum and frontal cortex. In another study, Bencherif et al.
(2004) also found a positive correlation between craving
and m-OR binding in lateral frontal cortices 4 days after
abstinence. We have identified slightly elevated cortical
binding of the non-selective opioid receptor ligand
[
11C]DPN in alcoholics while still on alcohol, and the bind-
ing levels decreased over the time course of 4 weeks of absti-
nence (Willoch et al., unpublished data). All these studies are
consistent with an influence of alcohol on OR status.
Receptor occupancy
The PET ligands and administered drugs can compete for
the same binding site on the receptors. The competitional
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occupancy of a given drug. Nalmefene is a non-selective
OR antagonist with a stronger binding to d-OR than that
of naltrexone (DeHaven-Hudkins et al., 1990) and with
a longer plasma half-life (Dixon et al., 1987). Because of its
pharmacological properties, nalmefene has been proposed
to offer an advantage in the treatment of alcoholism.
Recently, a study was undertaken to determine the receptor
occupancy of nalmefene at the m-OR in the brain in healthy
volunteers using the m-agonist [
11C]CAF (Ingman et al.,
2005). Both single and repeated nalmefene oral dosing
led to a very high m-OR occupancy and 50h after admin-
istration, the occupancy was still  50% while plasma
concentrations were negligible. This discrepancy is probably
due to a slow dissociation rate of nalmefene from m-ORs.
These results support an earlier study of receptor
occupancy of a single intravenous bolus applying a
simple dual-detector system and [
11C]CAF as ligand
(Kim et al., 1997).
Abuse of m-opioids is increasingly manifested as a major
health issue due to the large potential for a strong physical
addiction developed to this drug. From early work that
led to the development of methadone maintenance treat-
ment for heroin addiction in the 1960s, it is known that
m-selective agonists with long-acting pharmacokinetics such
as methadone or partial agonists (buprenorphine) are the
most effective treatments for this disorder (Dole et al.,
1966; Kreek et al., 2002). A successful pharmacotherapeutic
treatment is dependent on a sustained and steady effect on
the ORs and requires a tailored dose regimen. The use of
PET molecular imaging with opioid-selective radioligands
will be important for evaluating substitution therapy
regimens and developing improved medications by corre-
lating the dose and efficacy of the pharmacological agent
with the resulting receptor occupancy (Kling et al., 2000;
Zubieta et al., 2000; Greenwald et al., 2003). Methadone is a
potent m-selective agonist (Quock et al., 1999) and a study
of its receptor occupancy when given to heroin addicts was
performed using [
18F]FCyF (m- and k-OR antagonist).
Relative to healthy non-treated controls a reduction in
receptor availability of 19–32% was found. The degree of
receptor occupancy correlated with methadone plasma
levels (Kling et al., 2000). In contrast, no difference in
[
11C]DPN (m-, d- and k-antagonist) binding was seen in
a study between opioid-dependent subjects on methadone
compared to drug-free healthy volunteers (Melichar et al.,
2005). The lack of change in binding was verified in an
animal study. The high efficacy of methadone expressed at
a low fraction of receptor occupancy, was suggested by
Melichar et al. as the most likely explanation for the
missing displacement of PET ligand binding. Some effects
must be related to the dissimilar properties of the two
tracers used, and to what degree these are displaced from
the OR. Hume et al. (2007) studied the receptor occupancy
at clinical doses of oxycodone (m- and k-receptor agonist),
morphine (m-receptor agonist) and buprenorphine (partial
agonist at the m-receptor and antagonist at the d- and
k-receptors) in rats. In vivo binding of [
11C]DPN was not
significantly reduced after treatment with the full agonists,
but was reduced by  90% by buprenorphine. Thus the
study supports the minimal competition between highly
potent agonists and [
11C]DPN.
Buprenorphine does effectively displace the m-agonist
tracer [
11C]CAF (Greenwald et al., 2003, 2007). Up to 90%
receptor occupancy has been measured at stabilized clinical
doses of buprenorphine. The latter study (Greenwald
et al., 2007) investigated the duration of action and
receptor occupancy of buprenorphine in relation to with-
drawal symptoms; an occupancy of 50–60% of the receptors
was required for adequate suppression of withdrawal
symptoms.
Conclusion and perspectives
Imaging of opioid receptors in the CNS has contributed to
delineate the in vivo neurochemistry of healthy humans.
Changes in regional OR function have been identified in
epilepsy, movement disorders, neurodegeneration, pain and
addiction and the neurobiological correlates of affective
and eating disorders have been disclosed. Furthermore, OR
imaging has proven valuable in drug administration and
dosage studies.
The field of non-invasive imaging is facing continued
efforts in the design of subclass selective tracers with faster
binding kinetics, as well as enhanced emphasis on
combining the knowledge from chemistry and pharmacol-
ogy subdisciplines in the design of better imaging protocols
in order to achieve more accurate determinations of the
imaging data. In general, PET data are available only to the
few centres having access to these techniques. The scientific
community would certainly profit not only from a detailed
description of the regional binding profiles of more
selective OR ligands, but also the presentation of such
data in available databases as presently done for fMRI
(Barinaga, 2003).
Apparently, the tracer properties in terms of OR subclass
selectivity and agonistic/antagonistic character dominate
the information that can be drawn from in vivo studies.
Currently, only two of the ligands available for application
in humans have pronounced selectivity for a single subclass
of OR; the d-OR-selective [
11C-Me]naltrindole and the
m-OR-selective [
11C]carfentanil of which only the latter has
been demonstrated to be applicable for quantitative
measurements. We conclude that the current major obstacle
in the field is presented by the inherent limitations of the
currently available tracers in reporting dynamic changes
in the availability of a single OR subclass in the CNS. Upon
solving these methodological challenges and limitations,
opioid receptor imagings should be applicable for further
and more detailed in vivo studies of brain pathology
involving the opioid signalling.
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